These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 18278812)

  • 1. Thromboembolic events with lenalidomide-based therapy for multiple myeloma.
    Menon SP; Rajkumar SV; Lacy M; Falco P; Palumbo A
    Cancer; 2008 Apr; 112(7):1522-8. PubMed ID: 18278812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
    Larocca A; Cavallo F; Bringhen S; Di Raimondo F; Falanga A; Evangelista A; Cavalli M; Stanevsky A; Corradini P; Pezzatti S; Patriarca F; Cavo M; Peccatori J; Catalano L; Carella AM; Cafro AM; Siniscalchi A; Crippa C; Petrucci MT; Yehuda DB; Beggiato E; Di Toritto TC; Boccadoro M; Nagler A; Palumbo A
    Blood; 2012 Jan; 119(4):933-9; quiz 1093. PubMed ID: 21835953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thromboprophylaxis in multiple myeloma patients treated with lenalidomide - A systematic review.
    Al-Ani F; Bermejo JM; Mateos MV; Louzada M
    Thromb Res; 2016 May; 141():84-90. PubMed ID: 26986753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma.
    Niesvizky R; Martínez-Baños D; Jalbrzikowski J; Christos P; Furst J; De Sancho M; Mark T; Pearse R; Mazumdar M; Zafar F; Pekle K; Leonard J; Jayabalan D; Coleman M
    Leuk Lymphoma; 2007 Dec; 48(12):2330-7. PubMed ID: 18067007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma.
    Baz R; Li L; Kottke-Marchant K; Srkalovic G; McGowan B; Yiannaki E; Karam MA; Faiman B; Jawde RA; Andresen S; Zeldis J; Hussein MA
    Mayo Clin Proc; 2005 Dec; 80(12):1568-74. PubMed ID: 16342649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
    Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
    Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of thrombosis with lenalidomide and its prevention with aspirin.
    Hirsh J
    Chest; 2007 Jan; 131(1):275-7. PubMed ID: 17218586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network.
    Palumbo A; Falco P; Corradini P; Falcone A; Di Raimondo F; Giuliani N; Crippa C; Ciccone G; Omedè P; Ambrosini MT; Gay F; Bringhen S; Musto P; Foà R; Knight R; Zeldis JB; Boccadoro M; Petrucci MT;
    J Clin Oncol; 2007 Oct; 25(28):4459-65. PubMed ID: 17785703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lenalidomide and venous thrombosis in multiple myeloma.
    Knight R; DeLap RJ; Zeldis JB
    N Engl J Med; 2006 May; 354(19):2079-80. PubMed ID: 16687729
    [No Abstract]   [Full Text] [Related]  

  • 11. Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis.
    Zonder JA; Barlogie B; Durie BG; McCoy J; Crowley J; Hussein MA
    Blood; 2006 Jul; 108(1):403; author reply 404. PubMed ID: 16790586
    [No Abstract]   [Full Text] [Related]  

  • 12. Lenalidomide plus dexamethasone vs. lenalidomide plus melphalan and prednisone: a retrospective study in newly diagnosed elderly myeloma.
    Gay F; Vincent Rajkumar S; Falco P; Kumar S; Dispenzieri A; Petrucci MT; Gertz MA; Boccadoro M; Keith Stewart A; Palumbo A
    Eur J Haematol; 2010 Sep; 85(3):200-8. PubMed ID: 20477865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
    Durie BGM; Hoering A; Abidi MH; Rajkumar SV; Epstein J; Kahanic SP; Thakuri M; Reu F; Reynolds CM; Sexton R; Orlowski RZ; Barlogie B; Dispenzieri A
    Lancet; 2017 Feb; 389(10068):519-527. PubMed ID: 28017406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
    Palumbo A; Rajkumar SV; Dimopoulos MA; Richardson PG; San Miguel J; Barlogie B; Harousseau J; Zonder JA; Cavo M; Zangari M; Attal M; Belch A; Knop S; Joshua D; Sezer O; Ludwig H; Vesole D; Bladé J; Kyle R; Westin J; Weber D; Bringhen S; Niesvizky R; Waage A; von Lilienfeld-Toal M; Lonial S; Morgan GJ; Orlowski RZ; Shimizu K; Anderson KC; Boccadoro M; Durie BG; Sonneveld P; Hussein MA;
    Leukemia; 2008 Feb; 22(2):414-23. PubMed ID: 18094721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How to prevent deep vein thrombosis in myeloma patients receiving thalidomide or lenalidomide.
    Kastritis E; Dimopoulos M
    Leuk Lymphoma; 2007 Dec; 48(12):2295-7. PubMed ID: 18066998
    [No Abstract]   [Full Text] [Related]  

  • 16. Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma.
    Dimopoulos MA; Cheung MC; Roussel M; Liu T; Gamberi B; Kolb B; Derigs HG; Eom H; Belhadj K; Lenain P; Van der Jagt R; Rigaudeau S; Dib M; Hall R; Jardel H; Jaccard A; Tosikyan A; Karlin L; Bensinger W; Schots R; Leupin N; Chen G; Marek J; Ervin-Haynes A; Facon T
    Haematologica; 2016 Mar; 101(3):363-70. PubMed ID: 26659916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens.
    Bagratuni T; Kastritis E; Politou M; Roussou M; Kostouros E; Gavriatopoulou M; Eleutherakis-Papaiakovou E; Kanelias N; Terpos E; Dimopoulos MA
    Am J Hematol; 2013 Sep; 88(9):765-70. PubMed ID: 23757261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thromboprophylaxis prescribing and thrombotic event rates in multiple myeloma patients treated with lenalidomide or thalidomide at a specialist cancer hospital.
    Alexander M; Teoh KC; Lingaratnam S; Kirsa S; Mellor JD
    Asia Pac J Clin Oncol; 2013 Jun; 9(2):169-75. PubMed ID: 22998589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.
    Kumar SK; Berdeja JG; Niesvizky R; Lonial S; Laubach JP; Hamadani M; Stewart AK; Hari P; Roy V; Vescio R; Kaufman JL; Berg D; Liao E; Di Bacco A; Estevam J; Gupta N; Hui AM; Rajkumar V; Richardson PG
    Lancet Oncol; 2014 Dec; 15(13):1503-1512. PubMed ID: 25456369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lenalidomide and venous thrombosis in multiple myeloma.
    Rajkumar SV; Blood E
    N Engl J Med; 2006 May; 354(19):2079-80. PubMed ID: 16696148
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.